Navigation Links
Cepheid Reports 2009 First Quarter Results
Date:4/23/2009

19 6,802 Accrued compensation (1,996) (2,730) Deferred revenue (563) (346) ----- ----- Net cash provided by (used in) operating activities 3,178 (1,654) ----- ------- Cash flows from investing activities: Capital expenditures (1,420) (4,674) Payments for technology licenses (1,500) - Cost of acquisition, net of cash acquired (148) - Proceeds from maturities of marketable securities - 2,550 Proceeds from the sale of fixed assets 8 24 Transfer to unrestricted cash 1,500 517 ----- ----- Net cash used in investing activities (1,560) (1,583) ------- ------- Cash flows from financing activities: Net proceeds from the issuance of common shares and exercise of stock options and awards 1,551 6,732 Principal payments of bank borrowing (41) - Principal payments of notes payable - (4) ----- ----- Net cash provided by financing activities 1,510 6,728 ----- ----- Effect of exchange rate change on cash 202 33 ----- ----- Net increase in cash and cash equivalents
'/>"/>
SOURCE Cepheid
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Cepheid Enters Into Five-Year Agreement With Northrop Grumman for the Purchase of Anthrax Test Cartridges for Use in United States Postal Service Biohazard Detection Systems
2. Cepheid to Present at Thomas Weisel Partners Healthcare Conference
3. Cepheid Enters Agreement To Exclusively License HPV Portfolio Developed by Quantovir AB
4. Cepheid to Present at William Blair Small-Cap Growth Stock Conference
5. Cepheid to Present at the Piper Jaffray 19th Annual Healthcare Conference
6. Cepheid Receives Health Canada Medical Device License for Xpert MRSA(TM) Test and GeneXpert(R) System
7. Cepheid Schedules Teleconference and Webcast for 2007 Fourth Quarter and Full Year Results
8. Cepheid Appoints Senior VP, Chief Financial Officer to Management Team
9. Cepheid and Instrumentation Laboratory Introduce Xpert(TM) HemosIL(R) FII & FV Assay to European Clinical Testing Market
10. Cepheid Reports Fourth Quarter and Full Year 2007 Results
11. Cepheid to Present at Cowen and Companys 28th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Yonkers, NY (PRWEB) May 23, 2013 ... GRAPHALLOY® self-lubricating bushings mounted in stainless ... and self-lubricating properties of GRAPHALLOY with the application ... GRAPHALLOY Stainless Steel Pillow Blocks work exceptionally ... other corrosive or hostile liquids such as acids, ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 PI’s ... wide and provide 15 mm travel range with ... The small dimensions make these new positioners the ... spaces. A vacuum rated version is also available. ... specifications and datasheets can be found at: , ...
(Date:5/23/2013)... FL (PRWEB) May 23, 2013 On ... made trips to supermarkets to search for the growing ... store aisles. Results from a year long study were ... level in foods, specifically meats, over previous years. For ... how the growth of antibiotic resistant bacteria in food, ...
(Date:5/23/2013)... DIEGO , May 23, 2013  Verenium Corporation ... company focused on the development and commercialization of high-performance ... , Chief Financial Officer, will present at two upcoming ... Mr. Black will present at the Second Annual Marcum ... the Grand Hyatt Hotel in New York City.  The ...
Breaking Biology Technology:Graphite Metallizing Now Offers GRAPHALLOY® Stainless Steel Pillow Blocks for Success in Submersible Applications 2Graphite Metallizing Now Offers GRAPHALLOY® Stainless Steel Pillow Blocks for Success in Submersible Applications 3Precision Positioning System Uses Miniaturezed Piezo Linear Motor: LPS-24 Linear Stage by PI 2Acne Cream, Probiotic Action Shares News on How Some Food may Breed Acne Causing Bacteria 2Verenium To Present At Two Upcoming Conferences 2Verenium To Present At Two Upcoming Conferences 3
... 1:30 p.m. Eastern Time Today, GAITHERSBURG, Md., March ... financial results and corporate progress for,the full year ended ... we have further demonstrated that Iomai,s,vaccine and immunostimulant patches ... president and chief executive officer,of Iomai. "This lays the ...
... HILLS, Mass., March 6 Joseph F. Finn, ... of ActivBiotics, announced,today that the Office of Orphan ... has granted Orphan Drug Designation for M40403 for ... oral mucositis (OM),in cancer patients., The development ...
... EntreMed, Inc.,(Nasdaq: ENMD ), a clinical-stage pharmaceutical ... inflammatory diseases, today,reported results for the three months ... http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO ), For fiscal year ... 2006. For the year ended December 31, 2007, ...
Cached Biology Technology:Iomai Announces Year-End 2007 Financial Results and Business Progress 2Iomai Announces Year-End 2007 Financial Results and Business Progress 3Iomai Announces Year-End 2007 Financial Results and Business Progress 4Iomai Announces Year-End 2007 Financial Results and Business Progress 5Iomai Announces Year-End 2007 Financial Results and Business Progress 6ActivBiotics Receives FDA Orphan Drug Designation for Superoxide Dismutase Mimetic, M40403, in Oral Mucositis of Cancer 2ActivBiotics Receives FDA Orphan Drug Designation for Superoxide Dismutase Mimetic, M40403, in Oral Mucositis of Cancer 3EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results 2EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results 3EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results 4EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results 5
(Date:5/23/2013)... Frontiers in Plant Science , ... gene content and promoter evolution among grasses , ... of stretches of DNA that undergo little change in ... not code for any proteins. Some of these evolutionarily ... to regulate the expression of other genes or the ...
(Date:5/23/2013)... new mechanism by which estrogen suppresses lipid synthesis in ... new approach toward treating certain liver diseases. , ... they are changing long-held views in the field. Study ... journal Science Signaling . , "The dogma in ... that only receptors located in the nucleus respond to ...
(Date:5/23/2013)... medics have succeeded in treating cerebral palsy with autologous ... damage, a 2.5 year old boy had been in ... survival. Just two months after treatment with the cord ... the following months, the child learned to speak simple ... from a Korean study, dispel the long-held doubts about ...
Breaking Biology News(10 mins):Frontiers news briefs: May 23 2Frontiers news briefs: May 23 3UCI study reveals new mechanism for estrogen suppression of liver lipid synthesis 2First successful treatment of pediatric cerebral palsy with autologous cord blood 2
... assistant at the University of North Carolina Hospitals arrived ... a glowing track record in helping to repair heart ... perform gastric bypass operations for morbid obesity. , The ... Surgical System, manufactured by Intuitive Surgical. UNC currently is ...
... University of North Carolina Hospitals arrived in February sporting ... record in helping to repair heart valves, remove cancerous ... operations for morbid obesity. , The new arrival is ... by Intuitive Surgical. UNC currently is the only gynecological ...
... aquatic plants respond to plant disease and climate ... say plant pathologists with The American Phytopathological Society ... University, Ithaca, NY, many aquatic plants possess unique ... study, plant pathologists may be able to apply ...
Cached Biology News:FDA: 'Highly Unlikely' Green Tea Lowers Cancer Risk 2FDA: 'Highly Unlikely' Green Tea Lowers Cancer Risk 3Screen all at risk for HIV, plus pregnant women 2Screen all at risk for HIV, plus pregnant women 3
... Sepharose 4B, 10 ... purification of calmodulin-binding ... of calmodulin-regulated proteins ... cells. Category: Chromatography ...
Immunogen: Secretory component isolated from human colostrum. Storage: 4 C...
... The PinPoint™ Vector Sequencing Primer is ... PinPoint™ Xa Vectors (Cat.# V2031, V2051, V2061). ... Xa site at nucleotides 325343, approximately 4050 ... region and can be used to determine ...
Negative Control, eluted and packaged aseptically in 20l of 10mM Tris-HCL, pH 8.0, 1 mM EDTA, 5 years at either 4°C or -20°C...
Biology Products: